BioSpace News Archive

Genflow Biosciences Plc (“Genflow” or “the Company”) (LSE:GENF) (OTCQB:GENFF), today announced the receipt of written comments from the Federal Agency for Medicines and Health Products,

Evaxion Biotech A/S today announced a collaboration with Afrigen Biologics (Afrigen).

LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT ) (“LIXTE”), today announced a Phase 1b collaborative clinical trial to assess whether adding Lixte’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).

Femasys Inc. today announced the achievement of First-Patient-In for its pivotal clinical trial evaluating FemBloc ® , a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control for women.

As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition.

Charles River Laboratories International, Inc. (NYSE: CRL) announced that it will host a virtual Meeting with Management on Thursday, September 21st, beginning at 8:30 a.m. ET.

A global research study is now available in Tamarac, Fla., for an investigational treatment to help patients with a history of atrial fibrillation (AFib) decrease their risk of stroke.

Hillhurst Biopharmaceuticals, Inc. today announced the award of an approximately $3 million Phase 2b SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Mitsubishi Tanabe Pharma Canada is proud to support the development of a new artificial intelligence program designed to analyze de-identified electronic medical records and identify individuals for which follow-up investigations for Amyotrophic Lateral Sclerosis, or referral to a specialty centre may be clinically appropriate.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results for the six-month period ended June 30, 2023, and provides an update on its product pipeline and upcoming plans.